Analysis of hydroxy sphingomyelin

Sphingomyelin (SM) with N-α-hydroxy fatty acyl residues (hSM) has been shown to occur in mammalian skin and digestive epithelia. However, the metabolism and physiological relevance of this characteristic SM species have not been fully elucidated yet. Here, we show methods for mass spectrometric characterization and quantification of hSM. The hSM in mouse skin was isolated by TLC. The hydroxy hexadecanoyl residue was confirmed by electron impact ionization-induced fragmentation in gas chromatography-mass spectrometry. Mass shift analysis of acetylated hSM by time of flight mass spectrometry revealed the number of hydroxyl groups in the molecule. After correcting the difference in detection efficacy, hSM in mouse skin and intestinal mucosa were quantified by liquid chromatography-tandem mass spectrometry, and found to be 16.5 ± 2.0 and 0.8 ± 0.4 nmol/μmol phospholipid, respectively. The methods described here are applicable to biological experiments on hSM in epithelia of the body surface and digestive tract

L-carnitine prevents lenvatinib-induced muscle toxicity without impairment of the anti-angiogenic efficacy

Lenvatinib is an oral tyrosine kinase inhibitor that acts on multiple receptors involved in angiogenesis. Lenvatinib is a standard agent for the treatment of several types of advanced cancers; however, it frequently causes muscle-related adverse reactions. Our previous study revealed that lenvatinib treatment reduced carnitine content and the expression of carnitine-related and oxidative phosphorylation (OXPHOS) proteins in the skeletal muscle of rats. Therefore, this study aimed to evaluate the effects of L-carnitine on myotoxic and anti-angiogenic actions of lenvatinib. Co-administration of L-carnitine in rats treated with lenvatinib for 2 weeks completely prevented the decrease in carnitine content and expression levels of carnitine-related and OXPHOS proteins, including carnitine/organic cation transporter 2, in the skeletal muscle. Moreover, L-carnitine counteracted lenvatinib-induced protein synthesis inhibition, mitochondrial dysfunction, and cell toxicity in C2C12 myocytes. In contrast, L-carnitine had no influence on either lenvatinib-induced inhibition of vascular endothelial growth factor receptor 2 phosphorylation in human umbilical vein endothelial cells or angiogenesis in endothelial tube formation and mouse aortic ring assays. These results suggest that L-carnitine supplementation could prevent lenvatinib-induced muscle toxicity without diminishing its antineoplastic activity, although further clinical studies are needed to validate these findings

血液中リゾリン脂質の産生制御を介して肥満抑制効果を発揮する機能性食品の開発

金沢大学医薬保健研究域医学系リゾホスファチジン酸（LPA）とスフィンゴシン1-リン酸（S1P）は，細胞内外でのシグナル分子として細胞の機能発現に重要な働きを担う脂質分子である。本研究では，様々な病気につながる肥満にLPAあるいはS1Pの産生異常が関係すると想定し，ポリフェノール類で生体内のLPAあるいはS1P量を是正することで脂肪新生を抑制できるか検討した．その結果，LPAとS1Pの両方または何れか一方の産生酵素の活性を阻害したケルセチン，フィセチン，ルテオリン，レスベラトロールおよびクルクミンを前駆脂肪細胞に添加することで脂肪細胞への分化およびトリアシルグリセロール合成が抑制されることを明らかとした．Lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) are bioactive lipid mediators that are crucial for the regulation of diverse biological processes. We assumed that abnormal production of LPA and S1P contribute to fat development in obesity, which leads to various diseases such as arteriosclerosis, coronary artery disease, diabetes and hypertension. By screening from commercially available polyphenols, we found that querctin, kempherol, robinetin, cathekin, propyl gallate, luteolin, resveratrol, curcumin, myricetin have inhibitory activities to LPA- and/or S1P-producing enzymes. In these polyphenols, quercetin, fisetin, luteolin, resveratrol and curcumin prevent cell differentiation and triacylglycerol synthesis, showing the foods contained these polyphenols are useful as anti-obesity food

Chronic Treatment with Metformin Has No Disrupting Effect on the Hepatic Circadian Clock in Mice

Background and Objectives: The antidiabetic agent metformin is known to activate AMP-activated protein kinase (AMPK) in various tissues. Because AMPK can modulate intracellular circadian clocks through regulating the stability of clock components, a single dose of metformin has been reported to affect circadian clocks in the peripheral tissues. In this study, therefore, we investigated whether chronic treatment with metformin causes the impairment of circadian clocks, especially if given at an inappropriate time. Materials and Methods: Non-diabetic C57BL/6J mice were allowed access to food only during 4 h at the beginning of the dark period, and repeatedly i.p. injected with a nearly maximum non-toxic dose of metformin, once daily either at 4 h after the beginning of the dark period or at the beginning of the light period. Diabetic ob/ob mice were given free access to food and treated with metformin in drinking water. Results: Under the controlled feeding regimen, 8-day treatment with metformin did not alter the mRNA expression rhythms of clock genes in both liver and adipose tissue of C57BL/6J mice, regardless of dosing time. In addition, chronic treatment with metformin for 2 weeks affected hepatic AMPK activation rhythm but did not disrupt the circadian clocks in the liver and adipose tissues of the ob/ob mice. Conclusions: These results mitigate concerns that treatment with metformin impairs peripheral circadian clocks, although confirmation is needed in humans